**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 72103

**Manuscript Type:** CASE REPORT

**Local hyperthermia combined with chemotherapy for the treatment of multiple recurrences of *undifferentiated pleomorphic sarcoma*: A case report**

Zhou YT *et al.* Treatment of multiple recurrences of *UPS*

Yi-Ting Zhou, Ruo-Yu Wang, Yao Zhang, Dong-Yi Li, Jian Yu

**Yi-Ting Zhou, Jian Yu,** Hyperthermia Center, The Affiliated Zhongshan Hospital of Dalian University, Dalian 110006, Liaoning Province, China

**Ruo-Yu Wang,** Department of Medical Oncology, The Affiliated Zhongshan Hospital of Dalian University, Dalian 110006, Liaoning Province, China

**Yao Zhang, Dong-Yi Li,** Department of Bone and Soft Tissue Oncology, The Affiliated Zhongshan Hospital of Dalian University, Dalian 110006, Liaoning Province, China

**Author contributions:** Zhou YT and Yu J were the patient’s medical oncologists, reviewed the literature and drafted the manuscript; Zhang Y and Li DY were the patient’s surgeons, performed the surgery and analyzed the results; Wang RY analyzed and interpreted the imaging findings, reviewed the literature and drafted the manuscript; Wang RY and Yu J were responsible for the revision of the manuscript for important intellectual content; all authors issued final approval for the version to be submitted.

**Corresponding author: Jian Yu, MMed, Chief Doctor, Professor,** Hyperthermia Center, Affiliated Zhongshan Hospital of Dalian University, No. 6 Jiefang Street, Dalian 110006, Liaoning Province, China. dlyujian1127@163.com

**Received:** October 6, 2021

**Revised:** December 19, 2021

**Accepted:** February 15, 2022

**Published online:** March 26, 2022

**Abstract**

BACKGROUND

*Undifferentiated pleomorphic sarcoma (UPS)* is a type of soft tissue sarcoma, the histologic origin and differentiation direction of which are still unclear. There are few treatment options for *UPS* other than surgery. Herein we describe a patient who had multiple recurrences of *UPS* postoperatively, but R0 resection was achieved by local hyperthermia combined with chemotherapy, thus providing a new treatment approach for similar situations.

CASE SUMMARY

A 65-year-old man sought evaluation from a physician for a mass on his right back. After surgery, the pathologic diagnosis was fibrosarcoma. During the follow-up evaluations until 2021, the patient had four relapses of varying degrees. Postoperative pathology confirmed the recurrence of *UPS* on the right back. In March 2021, he underwent local hyperthermia combined with two cycles of chemotherapy for recurring lesions. After magnetic resonance imaging re-examination and preoperative examination, the patient chose surgery again. During the operation, the tumors were easy to excise, the amount of bleeding decreased significantly, and the pathologic evaluation confirmed that one of the specimens was an R0 excision.

CONCLUSION

Local hyperthermia combined with chemotherapy enables R0 resection to be achieved in patients with advanced *UPS* recurrence.

**Key Words:** *Undifferentiated pleomorphic sarcoma*; Local hyperthermia; Chemotherapy; R0 resection; Case report

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Zhou YT, Wang RY, Zhang Y, Li DY, Yu J. Local hyperthermia combined with chemotherapy for the treatment of multiple recurrences of *undifferentiated pleomorphic sarcoma*: A case report. *World J Clin Cases* 2022; 10(9): 2916-2922

**URL:** https://www.wjgnet.com/2307-8960/full/v10/i9/2916.htm

**DOI:** https://dx.doi.org/10.12998/wjcc.v10.i9.2916

**Core Tip:** *Undifferentiated pleomorphic sarcoma* is a type of soft tissue sarcoma, but the histologic origin and direction of differentiation are still unclear. Patients with locally advanced, unresectable, or metastatic disease have a poor prognosis, and there are few treatment options available. Clinically, local hyperthermia combined with chemotherapy can be used to achieve surgical R0 resection in this type of patient.

**INTRODUCTION**

Undifferentiated polymorphic sarcoma, once known as malignant fibroblastoma, has been officially replaced by *Undifferentiated pleomorphic sarcoma (UPS)* malignant fibrous histiocytoma according to the latest classification of related sarcomas in 2013 and is defined as a soft tissue sarcoma type however, the histologic origin and direction of differentiation direction of which are still unclear[1,2]. At present, there are many clinical treatment methods for *UPS* (primarily surgical resection with adjuvant radiotherapy and chemotherapy), but the postoperative recurrence and metastasis rates are high and the prognosis is poor. In addition to early detection and complete tumor resection, effective measures to reduce recurrence rates, facilitate surgery, and achieve R0 resection are still lacking, representing a significant challenge.

Herein, we report a patient with advanced *UPS* who was admitted to the Hyperthermia Center of Zhongshan Hospital affiliated with Dalian University and treated with local hyperthermia combined with chemotherapy. The patient then proceeded with surgery, and R0 resection was achieved.

**CASE PRESENTATION**

***Chief complaints***

A 65-year-old elderly male patient was admitted to the hospital 6 years after the first surgery to remove a pleomorphic sarcoma from the right side of his back, and he experienced recurrence 4 mo after the last surgery.

***History of present illness***

The patient underwent primary mass resection from the right back in October 2015. The pathologic evaluation of the surgical specimen revealed fibrosarcoma; the specific stage and immunohistochemical results were not available. In November 2017, December 2018, September 2019, and August 2020, the patient underwent extended resection of soft tissue masses from the right back due to recurrence. The pathologic diagnoses indicated *UPS* recurrence. After surgery, 2 cycles of doxorubicin + cisplatin chemotherapy, 1 cycle of ifosfamide chemotherapy (specific dose unknown), 2 cycles of gemcitabine + docetaxel chemotherapy (specific dose unknown), anlotinib hydrochloride anti-vascular generative therapy, and bevacizumab + pembrolizumab immunotherapy were administered, but the efficacy was poor. The patient was referred to our hospital for further treatment.

***History of past illness***

The patient was diagnosed with type 2 diabetes several years after radical resection of renal cancer.

***Personal and family history***

No data were available.

***Physical examination***

The right back had several well-healed, old surgical scars with no erythema, swelling, or ulcerations. At the level of the 12th rib along the right posterior subaxillary line, a palpable, tender, round-like mass approximately 3 cm in diameter was noted. An ellipsoidal, tender mass, approximately 4 cm in diameter, was palpable at the lateral margin of the lower right scapula and the medial side of the scapula. There was no apparent limitation in thoracic mobility, and breath sounds were minimal in both lungs.

***Laboratory examinations***

No abnormalities in tumor markers were found.

***Imaging examinations***

Magnetic resonance imaging (MRI) showed that the right subscapular muscle, infraspinatus muscle, teres major, and latissimus dorsi muscle had local structural disorder. The images revealed the following: Patchy and elliptical abnormal signals; equal or slightly low signals on T1-weighted images; high signals on T2-weighted images; slightly higher signals on DWI; and similar signals or a low signal on ADC. Part of the boundary was clear; and the largest lesion was approximately 5.9 cm in diameter.

**FINAL DIAGNOSIS**

Based on both the clinical features and postoperative pathology (Figure 1), the patient was diagnosed with *UPS* recurrence.

**TREATMENT**

Local hyperthermia (BSD-2000 deep hyperthermia; 420 Hz; 40 min/session; 3 times/wk) treatment was delivered to the area of recurrence on the back, combined with eribulin (2 mg on d1 and 8) chemotherapy for 2 cycles. After preoperative examination, enlarged resection of the mass on the right back was performed.

**OUTCOME AND FOLLOW-UP**

The findings from resection of the right dorsal recurrent lesion were as follows (Figure 2A): There was a mass approximately 3 cm × 3 cm × 2 cm in size at the level of the flat 12 ribs on the right back. The mass was opened, appearing red and white in color on the cut surface, with scar-like tissue and a tough texture. Intraoperative frozen pathology revealed the following: Heterotypic cells were noted in the lower cut edge of the right lower dorsal mass; no tumor involvement at the resection margins of the remaining (upper, inner, outer, and bottom) tumor on the right lower back; and no tumor residue at the incision; A mass approximately 5 cm × 4 cm × 3 cm in size was noted on the lateral edge of the right dorsal subscapularis. After the mass was opened, the cut surface appeared red and white in color with oval-shaped, fish-like tissue and a tough texture (Figure 2B). Intraoperative frozen pathology revealed the following: Heterotypic cells on the upper and bottom cut edges of the right dorsal mass but no tumor involvement at the lower, inner, and outer cut margins; A mass approximately 4 cm × 4 cm × 3 cm in size was noted in the right dorsal scapula within the internal border muscle. The mass was cut open, and the cut surface appeared red and white in color with ellipsoidal, fish-like tissue and a tough texture. Intraoperative frozen pathology revealed the following: No tumor tissue was seen in the upper, lower, outer, or bottom of the right dorsal mass.

The surgeons reported that the lesion had clear boundaries with normal tissue, which was easy to dissect, and the intraoperative bleeding volume was significantly reduced, at approximately 200 mL. The postoperative pathologic diagnosis revealed that the *UPS* had recurred. The patient’s condition was relatively stable. The last follow-up evaluation was 31 August, 2021.

**DISCUSSION**

*UPS* is derived from primitive undifferentiated mesenchymal cells and lacks specific immunohistochemical markers[3]. Immunohistochemically, Vim, CD68, AAT, and AACT are usually positive, while epithelial markers such as CK5/6 and SMA are generally negative[4]. It is a high-degree malignant tumor; detection and early treatment are key[5]. Complete surgical resection is the most important treatment for *UPS*, and it is also an effective treatment method to reduce recurrence and metastasis. The minimum resection margin should be at least 10 mm to minimize the risk of local recurrence and metastasis[6]. In patients who have resectable soft tissue sarcomas that are detected early, radical resection combined with chemotherapy or radiation improves the 5-year survival rate. For patients who have advanced soft tissue sarcoma but missed the opportunity for surgery or have repeated recurrences after surgery, comprehensive treatment can be considered, such as combined therapy with radiotherapy, chemotherapy, local hyperthermia, targeted therapy and immunotherapy. Nevertheless, the recurrence and metastasis rates of *UPS* remain high.

Local hyperthermia is a new, painless, noninvasive, green, and precise cancer treatment that can be administered after traditional treatment. The basic principle is to use all kinds of physical energy to produce a thermal effect in human tissues. The difference in temperature tolerance between normal cells and tumor cells can be used to kill tumor cells and avoid the destruction of normal tissue. As the fifth most common treatment after surgery, radiotherapy, chemotherapy, and biotherapy, local hyperthermia has been approved by the FDA and can be used either alone or in combination with radiotherapy and chemotherapy. During local hyperthermia treatment, blood vessels in the tumor dilate, blood circulation accelerates, and the cumulative concentration of internal chemotherapy drugs increases. Tumor hyperthermia also effectively inhibits DNA repair and the expression of multiple drug resistance, resulting in increased sensitivity of cancer cells to chemotherapeutic agents and reduced or reversed incidence of drug resistance in tumors; some chemotherapeutics can also achieve a synergistic antitumor effect[7]. Local hyperthermia focuses the antitumor effect of chemotherapy drugs in the heated tumor area. Issels *et al*[8] demonstrated for the first time in a phase 3 randomized trial that local hyperthermia combined with pre- and postoperative chemotherapy was clinically more effective than chemotherapy alone in a specific population of high-risk soft-tissue sarcoma patients. The use of local hyperthermia adjuvant therapy in tumor surgery can improve the local control rate and patient survival[9].

The patient presented herein had recurrent *UPS* postoperatively. The age, medical history, and site of onset were all consistent with the characteristics of *UPS*. This disease has a high degree of malignancy and can cause multiple recurrences after surgery. He had been treated with a variety of adjuvant chemotherapy regimens, all of which had poor efficacy, and serious adverse reactions were noted during treatment. Considering the actual situation of patients, local hyperthermia combined with Eribulin (a new chemotherapy drug) was given, which achieved good clinical effect. Eribulin is a synthetic analog of the soft seaweed B. Eribulin. It can inhibit microtubule polymerization through specific binding sites on β-tubulin, has antimitotic effects based on tubulin, prevents cells from transitioning to G2 and M stages, and disrupts the formation of mitotic spindles[10]. Kawai *et al*[11] reported a phase II study that compared pazopanib and trabectedin. Eribulin significantly improved the overall survival rate of patients with advanced sarcoma and has been gradually applied to the treatment of sarcoma. Although the lesion did not show significant shrinkage on MRI, the boundary of the lesion was clear, and there were multiple cystic necrotic areas inside the lesion, suggesting that the tumor activity in the lesion had been reduced (Figure 3). During the operation, it was found that the lesion could be easily removed, and the amount of bleeding was significantly reduced. Pathologic evaluation revealed that one of the sites was a successful R0 resection. This case shows that local hyperthermia combined with chemotherapy in *UPS* patients can cause tumor activity to decrease, can reduce the adhesions between the tumor and normal tissues, and can reduce intraoperative bleeding. It can provide a practical basis for increasing the R0 resection rate.

At the same time, this case also caused us to think more about the diagnosis, treatment and prognosis of *UPS*. At the 2021 Chinese Society of Clinical Oncology academic annual meeting, it was proposed that some types of soft tissue tumors show molecular changes, such as soft tissue tumors with PRDM10 rearrangement, which are mainly seen in low-grade *UPS*[12]. The study of Pazzaglia *et al*[13] proposed that the MET gene can predict the risk of metastasis in such patients at the genetic level. When their study divided the patients into prognostic subgroups, they found that the level of MET mRNA in metastatic patients was significantly higher than that in nonmetastatic patients. Regarding the treatment of *UPS*, in addition to the local hyperthermia combined with traditional chemotherapy strategy used for this patient, molecular targeted drugs and PD-1 and PD-L1 inhibitors have also gradually received attention. Molecular targeted drugs and PD-1 and PD-L1 inhibitors are also gradually becoming valued. For example, drugs such as apatinib, olazumab, lidafromus and anlotinib have shown significant efficacy in *UPS* treatment[14]. In 2021, a study on the efficacy of chidamine combined with the PD-1 inhibitor teriprizumab for the treatment of advanced soft tissue sarcoma (STS) conducted at Sun Yat-sen University found that after a follow-up of up to 40 wk, 3 of the 7 patients with advanced STS, 3 patients experienced partial remission, and 2 patients were in stable condition[15]. According to existing international studies, the synergistic effect of hyperthermia and immunotherapy on tumors such as pancreatic cancer and breast cancer has been confirmed[16-18]. However, there are no relevant reports for *UPS* treatment at present, so more basic and clinical research is needed to explore the synergistic effects of hyperthermia and immunotherapy in the future.

**CONCLUSION**

*UPS* has a high clinical misdiagnosis rate, and patients with locally advanced, unresectable, or metastatic disease have a poor prognosis and few treatment options[19]. Local hyperthermia combined with chemotherapy for multiple recurrences of undifferentiated sarcoma after surgery has been rarely reported in clinical practice. By reporting this case, we hope to provide new ideas for the treatment of postoperative recurrence of advanced *UPS*, which could help to optimize surgical opportunities and achieve R0 resection. Along with the application of molecular-pathological diagnosis, continuous prospective research on the use of hyperthermia combined with radiotherapy, chemotherapy, and immunotherapy will provide more options for the comprehensive management of *UPS*.

**ACKNOWLEDGEMENTS**

The authors would like to thank and acknowledge the patient and his family for taking part in this study.

**REFERENCES**

1 **Rosenberg AE**. WHO Classification of Soft Tissue and Bone, fourth edition: summary and commentary. *Curr Opin Oncol* 2013; **25**: 571-573 [PMID: 23942303 DOI: 10.1097/01.cco.0000432522.16734.2d]

2 **Jo VY**, Fletcher CD. WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition. *Pathology* 2014; **46**: 95-104 [PMID: 24378391 DOI: 10.1097/PAT.0000000000000050]

3 **Zhu Y**, Hao D, Tang X, Sun L. Undifferentiated high-grade pleomorphic sarcoma of ethmoid sinus: a case report and literature review. *Braz J Otorhinolaryngol* 2018; **84**: 389-392 [PMID: 28629789 DOI: 10.1016/j.bjorl.2017.05.004]

4 **Jiang WH**, Wen JM, Xu CW, Wang JC, Chen G. Clinicopathological analysis of undifferentiated pleomorphic sarcoma. *Linchuang yu Bingli Za Zhi* 2020; **40:** 83742-842 [DOI: 10.18535/jmscr/v6i11.94]

5 **Ren HH**, Wang XB. A case of undifferentiated pleomorphic sarcoma of the right scapula and literature review. *Shiyong Yixue Za Zhi* 2020; **37:** 530-2+77 [DOI: 10.4414/cvm.2015.00333]

6 **Fujiwara T**, Stevenson J, Parry M, Tsuda Y, Tsoi K, Jeys L. What is an adequate margin for infiltrative soft-tissue sarcomas? *Eur J Surg Oncol* 2020; **46**: 277-281 [PMID: 31627932 DOI: 10.1016/j.ejso.2019.10.005]

7 **He HJ**, He HF, Chen PD, Zhang YS, Huang CJ. High-power microwave hyperthermia combined with chemotherapy and radiotherapy for hip osteosarcoma. *Shiyong Yixue Za Zhi* 2008; 658-60 [DOI: 10.1109/icmmt.2012.6230027]

8 **Issels RD**, Lindner LH, Verweij J, Wust P, Reichardt P, Schem BC, Abdel-Rahman S, Daugaard S, Salat C, Wendtner CM, Vujaskovic Z, Wessalowski R, Jauch KW, Dürr HR, Ploner F, Baur-Melnyk A, Mansmann U, Hiddemann W, Blay JY, Hohenberger P; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC-STBSG); European Society for Hyperthermic Oncology (ESHO). Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. *Lancet Oncol* 2010; **11**: 561-570 [PMID: 20434400 DOI: 10.1016/S1470-2045(10)70071-1]

9 **Fan Q**, Ma B, Guo A. [Treatment of malignant or aggressive bone tumors with microwave induced hyperthermia]. *Zhonghua Wai Ke Za Zhi* 1997; **35**: 484-487 [PMID: 10678071]

10 **Niu XH**. Progress in the treatment of bone and soft tissue tumors. *Cancer Research on Prevention and Treatment* 2020; **47:** 1-5 [DOI: 10.1007/978-3-642-69210-9\_10]

11 **Kawai A**, Araki N, Naito Y, Ozaki T, Sugiura H, Yazawa Y, Morioka H, Matsumine A, Saito K, Asami S, Isu K. Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma. *Jpn J Clin Oncol* 2017; **47**: 137-144 [PMID: 28173193 DOI: 10.1093/jjco/hyw175]

12 **Puls F**, Pillay N, Fagman H, Palin-Masreliez A, Amary F, Hansson M, Kindblom LG, McCulloch TA, Meligonis G, Muc R, Rissler P, Sumathi VP, Tirabosco R, Hofvander J, Magnusson L, Nilsson J, Flanagan AM, Mertens F. PRDM10-rearranged Soft Tissue Tumor: A Clinicopathologic Study of 9 Cases. *Am J Surg Pathol* 2019; **43**: 504-513 [PMID: 30570551 DOI: 10.1097/PAS.0000000000001207]

13 **Pazzaglia L**, Novello C, Conti A, Pollino S, Picci P, Benassi MS. miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma. *Cell Oncol (Dordr)* 2017; **40**: 77-88 [PMID: 27900663 DOI: 10.1007/s13402-016-0306-4]

14 **Luo CL**, Li ZP. Research progress in molecular targeted therapy of soft tissue sarcoma. *Zhongguo Aizheng Za Zhi* 2019; **29:** 824-31 [DOI: 10.11569/wcjd.v27.i10.643]

15 **Que Y**, Zhang XL, Liu ZX, Zhao JJ, Pan QZ, Wen XZ, Xiao W, Xu BS, Hong DC, Guo TH, Shen LJ, Fan WJ, Chen HY, Weng DS, Xu HR, Zhou PH, Zhang YZ, Niu XH, Zhang X. Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma. *J Immunother Cancer* 2021; **9** [PMID: 33637599 DOI: 10.1136/jitc-2020-001696]

16 **Morrison AH**, Byrne KT, Vonderheide RH. Immunotherapy and Prevention of Pancreatic Cancer. *Trends Cancer* 2018; **4**: 418-428 [PMID: 29860986 DOI: 10.1016/j.trecan.2018.04.001]

17 **Elming PB**, Wittenborn TR, Horsman MR. OC-0053: Combining hyperthermia and checkpoint inhibitors: a method of increasing tumour immunogenicity? *Radiother Oncol* 2018; **127:** S22-S3 [DOI: 10.1016/s0167-8140(18)30363-3]

18 **Shi L**, Chen L, Wu C, Zhu Y, Xu B, Zheng X, Sun M, Wen W, Dai X, Yang M, Lv Q, Lu B, Jiang J. PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor. *Clin Cancer Res* 2016; **22**: 1173-1184 [PMID: 26933175 DOI: 10.1158/1078-0432.CCR-15-1352]

19 **Emambux S**, Italiano A. Clinical efficacy of eribulin mesylate for the treatment of metastatic soft tissue sarcoma. *Expert Opin Pharmacother* 2017; **18**: 819-824 [PMID: 28468516 DOI: 10.1080/14656566.2017.1326908]

**Footnotes**

**Informed consent statement:** Informed written consent was obtained from the patient for publication of this report and any accompanying images.

**Conflict-of-interest statement:** The authors declare that they have no conflicts of interest.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** October 6, 2021

**First decision:** December 10, 2021

**Article in press:** February 15, 2022

**Specialty type:** Oncology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Ding J, Menendez-Menendez J **S-Editor:** Liu JH **L-Editor:** A **P-Editor:** Liu JH

**Figure Legends**



**Figure 1 Postoperative pathological section (400 ×).**



**Figure 2 Three tumor specimens at the surgical removal site.** A: Tumor specimen; B: Maximum specimen profile.



**Figure 3 Preoperative chest MRI enhanced scan.** A: Cystic portion showed high signal in T2WI; B: Arterial phase, shows a multilocular solid and cystic lesion with slight enhancement on cyst wall; C: Venous phase; D: Delay period.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**